Neisseria gonorrhoeae (NG)

Gonococcal infections represent 106 million of the estimated 498 million new cases of curable STIs that occur globally every year.1

However, the emergence in N. gonorrhoeae of decreased susceptibility and resistance to existing treatment is cause for concern.

To foster effective prevention, diagnosis and control of gonococcal infections, Roche offers a multiplex assay that targets the NG species with high specificity.

The assay can be used together with the cobas® 4800 System as both a diagnostic and screening tool for ease of use, reliable results and quality control at every step.

Reference:

  1. World Health Organization (WHO). Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. http://apps.who.int/iris/bitstream/10665/44863/1/9789241503501_eng.pdf. 2012. Accessed May 13, 2016.